Accueil>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>GSK4028

GSK4028

Catalog No.GC30714

GSK4028 est le contrÔle négatif énantiomère de GSK4027, qui est une sonde chimique bromodomaine PCAF/GCN5, le pIC50 de GSK4028 est de 4,9 dans un test de transfert d'énergie par résonance de fluorescence (TR-FRET) résolu en temps.

Products are for research use only. Not for human use. We do not sell to patients.

GSK4028 Chemical Structure

Cas No.: 2079886-19-2

Taille Prix Stock Qté
10mM (in 1mL DMSO)
129,00 $US
En stock
5mg
117,00 $US
En stock
10mg
198,00 $US
En stock
25mg
405,00 $US
En stock
50mg
684,00 $US
En stock
100mg
1 125,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9. GSK4028 also demonstrates potency toward BRD4 BD1 and BRD9 inTR-FRET assay with pIC50s of <4.3 and 4.5±0.13, respectively[1].

[1]. Humphreys PG, et al. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem. 2017 Jan 26;60(2):695-709.

Avis

Review for GSK4028

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GSK4028

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.